FDA批准Datroway的乳癌高级治疗 其效果比化疗好37% FDA approves Datroway for advanced breast cancer, offering a 37% better outcome than chemo.

林业发展局批准了Datroway,这是对某些患有高级荷尔蒙受体阳性、HER2-阴性乳腺癌的成年病人的新治疗,这些病人以前曾接受过内分泌和化疗治疗。 The FDA has approved Datroway, a new treatment for certain adult patients with advanced hormone receptor-positive, HER2-negative breast cancer who have previously received endocrine-based and chemotherapy treatments. 根据TROPION-Breast01试验,Datroway比标准化疗降低37%的疾病发病或死亡风险,其副作用通常包括口痛、恶心和疲劳。 According to the TROPION-Breast01 trial, Datroway reduces the risk of disease progression or death by 37% compared to standard chemotherapy, with common side effects including mouth sores, nausea, and fatigue. 该药物的价格为每瓶4 891.07美元,预计两周后美国病人可以获得。 The drug is priced at $4,891.07 per vial and is expected to be available to U.S. patients in two weeks.